Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/06/21
Intercept Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/21
With Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?The Motley Fool • 04/23/21
Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/27/21
3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall StreetThe Motley Fool • 03/15/21
Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/25/21
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 02/25/21
Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business UpdateGlobeNewsWire • 02/25/21
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2021 - ICPTNewsfile Corp • 01/04/21
ICPT Final Deadline Today: Rosen, National Trial Lawyers, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPTNewsfile Corp • 01/04/21
DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the FirmPRNewsWire • 01/04/21